Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006168 · ClinicalTrials.gov registry record · Phase 3
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00006168: Completed Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00006168 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006168, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The major thrust is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone.
Interventions
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1994-01 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00006168 record still lists
NCT00006168 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Methotrexate is the first listed.
NCT00006168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006168 about?
NCT00006168 is a clinical study titled "Ursodiol-Methotrexate for Primary Biliary Cirrhosis". The major thrust is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone.
What is the current status of trial NCT00006168?
This trial is currently completed. It is a Phase 3 study. The study started on 1994-01. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00006168?
The interventions under investigation include: Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00006168?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia